A new molecular targeted therapeutic approach for renal cell carcinoma with a p16 functional peptide using a novel transporter system

Oncology Reports

Volumn 26, Issue 2, 2011, Pages 327-333

  Zennami, Kenji ^a   Yoshikawa, Kazuhiro ^a   Kondo, Eisaku ^c   Nakamura, Kogenta ^a   Yamada, Yoshiaki ^a   De Velasco, Marco A ^b   Tanaka, Motoyoshi ^b   Uemura, Hirotsugu ^b   Shimazui, Toru ^c   Akaza, Hideyuki ^d   Saga, Shinsuke ^a   Ueda, Ryuzo ^e   Honda, Nobuaki ^a  

^a AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF TSUKUBA   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

p16; PTD; Renal cell carcinoma

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; DRUG CARRIER; LYSYLGLUTAMYLTHREONYLTRYPTOPHYLTRYPTOPHYLGLUTAMYLTHREONYLTRYPTOPHYLTRYPTOPHYLTHREONYLGLUTAMYLTRYPTOPHYLSERYLGLUTAMINYLGLYCYLPROPYLGLYCYLARGINYLARGINYLARGINYLARGINYLARGINYLARGINYLARGINYLARGINYLARGININE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; KIDNEY CARCINOMA; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TUMOR REGRESSION; TUMOR XENOGRAFT;

AMINO ACID SEQUENCE; ANIMALS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYSTEAMINE; DRUG DELIVERY SYSTEMS; FEMALE; HELA CELLS; HUMANS; KIDNEY NEOPLASMS; MEMBRANE TRANSPORT PROTEINS; MICE; MICE, NUDE; MOLECULAR SEQUENCE DATA; MOLECULAR TARGETED THERAPY; PEPTIDES; PROTEIN STRUCTURE, TERTIARY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79958193514     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1290     Document Type: Article

References (31)

1. Wirth MP: Immunotherapy for metastatic renal cell carcinoma. Urol Clin North Am 20: 283-295, 1993.
2. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR and Louie AC: Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interieukin-2 therapy. J Clin Oncol 13: 688-696, 1995.
3. Medical Research Council Renal Cancer Collaborators: Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet 353: 14-17, 1999.
4. Motzer RJ, Bacik J, Murphy BA, Russo P and Mazumdar M: Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20: 289-296, 2002. (Pubitemid 34032623)
5. Akaza H, Tsukamoto T, Onishi T, Miki T, Kinouchi T and Naito S: A low-dose combination therapy of interleukin-2 and interferon-alpha is effective for lung metastasis of renal cell carcinoma: a multicenter open study. Int J Clin Oncol 11: 434-440, 2006. (Pubitemid 44974396)
6. Klapper JA, Downey SG, Smith FO, Yang JC, Hughes MS, Kammula US, Sherry RM, Royal RE, Steinberg SM and Rosenberg S: High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer 113: 293-301, 2008.
7. Gollob JA, Rathmell WK, Richmond TM, Marino CB, Miller EK, Grigson G, Watkins C, Gu L, Peterson BL and Wright JJ: Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. J Clin Oncol 25: 3288-3295, 2007. (Pubitemid 47325614)
8. Ryan CW, Goldman BH, Lara PN Jr, Mack PC, Beer TM, Tangen CM, Lemmon D, Pan CX, Drabkin HA and Crawford ED; Southwest Oncology Group: Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. J Clin Oncol 25: 3296-3301, 2007. (Pubitemid 47325615)
9. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM and Figlin RA: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115-124, 2007. (Pubitemid 46089672)
10. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D and Ravaud A; RECORD-1 Study Group: Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372: 449-456, 2008.
11. Escudier B, Szczylik C, Hutson TE, Demkow T, Staehler M, Rolland F, Negrier S, Laferriere N, Scheuring UJ, Cella D, Shah S, Bukowski RM: Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 27: 1280-1289, 2009.
12. Motzer RJ, Hudes GR, Curti BD, McDermott DF, Escudier BJ, Negrier S, Duclos B, Moore L, O'Toole T, Boni JP and Dutcher JP: Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma. J Clin Oncol 25: 3958-3964, 2007. (Pubitemid 47477274)
13. Green M and Loewenstein PM: Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. Cell 55: 1179-1188, 1988. (Pubitemid 19020070)
14. Frankel AD and Pabo CO: Cellular uptake of the tat protein from human immunodeficiency virus. Cell 55: 1189-1193, 1988. (Pubitemid 19020071)
15. Schwarze SR, Ho A, Vocero-Akbani A and Dowdy SF: In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285: 1569-1572, 1999.
16. Nagahara H, Vocero-Akbani AM, Snyder EL, Ho A, Latham DG, Lissy NA, Becker-Hapak M, Ezhevsky SA and Dowdy SF: Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration. Nat Med 12: 1449-1452, 1998. (Pubitemid 28553472)
17. Derossi D, Joliot AH, Chassaing G and Prochiantz A: The third helix of the Antennapedia homeodomain translocates through biological membranes. J Biol Chem 269: 10444-104450, 1994.
18. Wender PA, Mitchell DJ, Pattabiraman K, Pelkey ET, Steinman L and Rothbard JB: The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc Natl Acad Sci USA 97: 13003-13008, 2000.
19. Fisher PM, Krausz E and Lane DP: Cellular delivery of impermeable effector molecules in the form of conjugates with peptides capable of mediating membrane translocation. Bioconjug Chem 12: 825-841, 2001. (Pubitemid 33136850)
20. Joliot A and Prochiantz A: Transduction peptides: from technology to physiology. Nat Cell Biol 6: 189-196, 2004.
21. Kondo E, Seto M, Yoshikawa K and Yoshino T: Highly efficient delivery of p16 antitumor peptide into aggressive leukemia/ lymphoma cells using a novel transporter system. Mol Cancer Ther 3: 1623-1630, 2004. (Pubitemid 40136718)
22. Kondo E, Tanaka T, Miyake T, Ichikawa T, Hirai M, Adachi M, Yoshikawa K, Ichimura K, Ohara N, Moriwaki A, Date I, Ueda R and Yoshino T: Potent synergy of dual antitumor peptides for growth suppression of human glioblastoma cell lines. Mol Cancer Ther 7: 1461-1471, 2008.
23. Morris MC, Depollier J, Mery J, Heitz F and Divita G: A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat Biotechnol 19: 1173-1176, 2001. (Pubitemid 33115705)
24. Fahraeus R, Lain S, Ball KL and Lane DP: Characterization of the cyclin-dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule. Oncogene 16: 587-596, 1998. (Pubitemid 28062338)
25. Arvanitis DA and Spandidos DA: Deregulation of the G1/S phase transition in cancer and squamous intraepithelial lesions of the uterine cervix: a case control study. Oncol Rep 20: 751-760, 2008.
26. Kwon TK, Buchholz MA, Chrest FJ and Nordin AA: Staurosporine-induced G1 arrest is associated with the induction and accumulation of cyclin-dependent kinase inhibitors. cell Growth Differ 7: 1305-1313, 1996.
27. Donnellan R and Chetty R: Cyclin D1 and human neoplasia. Mol Pathol 51: 1-7, 1998. (Pubitemid 28157349)
28. Sherr CJ and Roberts JM: CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13: 1501-1512, 1999. (Pubitemid 29297917)
29. Ikuerowo SO, Kuczyk MA, von Wasielewski R, Shittu OB, Janas U, Machtens S, Serth J: p16INK4a expression and clinicopathologic parameters in renal cell carcinoma. Eur Urol 51: 732-737, 2007.
30. Scharml P, Struckmann K, Bendnar R, Fu W, Gasser T, Wilber K, Kononen J, Sauter G, Mihatsch MJ and Moch H: CDKNA2A mutation analysis, protein expression, and deletion mapping of chromosome 9p in conventional clear-cell renal carcinomas: evidence for a second tumor suppressor gene proximal to CDKN2A. Am J Pathol 158: 593-601, 2001. (Pubitemid 32158620)
31. Kawada Y, Nakamura M, Ishida E, Shimada K, Oosterwijk E, Uemura H, Hirao Y, Chul KS and Konishi N: Aberrations of the p14(ARF) and p16(INK4a) genes in renal cell carcinomas. Jpn J Cancer Res 92: 1293-1299, 2001. (Pubitemid 34036892)